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Abstract 
 
Aims: To analyze MP uptake and intracellular processing by the four main non-neuronal subclasses 
of the CNS [viz. oligodendrocyte precursor cells (OPCs), oligodendrocytes, astrocytes and 
microglia]. 
Materials and Methods: MP uptake and processing were studied in rat OPCs and 
oligodendrocytes, using fluorescence and transmission electron microscopy, and results collated 
with previous data from microglia and astrocytes. 
Results: Significant intercellular differences were observed between glial subtypes, with microglia 
demonstrating the most rapid/extensive particle uptake, followed by astrocytes, with OPCs and 
oligodendrocytes showing significantly lower uptake. Ultrastructural analyses suggest that MPs are 
extensively degraded in microglia but are relatively stable in other cells.  
Conclusions: Our findings have implications for use of the MP platform in a range of neural tissue 
engineering applications such as transfection, cell labeling and direct CNS biomolecule delivery. 
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Introduction 
 
Magnetic particles (MPs) have emerged in recent years as an important platform for advanced 
biomedical technology, due to innovations in their large-scale synthesis and complex surface 
functionalization [1,2]. These advanced materials are used in key applications such as drug/gene 
delivery, magnetic drug targeting, thermotherapies, stem cell targeting, and in diagnostic imaging 
(as contrast agents) [2–6]. The size and surface chemistry of MPs can be tailored for molecules with 
which they are ‘functionalized’, enabling the construction of multimodal particles that can mediate 
combinations of cellular applications, whilst retaining nanoscale dimensions [7]. The unique 
versatility achievable with their structural design therefore confers on MPs the ability to serve as a 
‘theragnostic platform’ to integrate therapeutic strategies with diagnostic methods such as MRI [8].  
 
Despite their proven therapeutic potential, the use of MPs for central nervous system or CNS (ie. 
brain and spinal cord) applications has been a relatively underexploited area to date [2]. Their utility 
is being increasingly demonstrated for a range of regenerative applications including neural 
progenitor/stem cell transplant imaging [9,10], gene delivery deploying novel 'magnetofection' 
methods [11–15] and diagnostic imaging in neurological injury [16]. However, there are critical 
gaps in our knowledge of fundamental parameters governing the utility of this emergent technology 
for CNS applications, especially the factors that determine MP uptake and intracellular processing 
in neural cells. The influence of parameters such as MP size, coating and charge on particle uptake 
have been studied in non-neural cell types [17-20] but the influence of neural cell subtype on 
particle uptake has never been assessed. This is especially pertinent when considering MP 
applications for CNS tissue; the latter is uniquely complex and contains several, specialist, 
interacting cell types meaning that data obtained from other physiological systems cannot be 
extrapolated to the CNS. The neurons mediate electrical conduction but a diverse population of 
non-neuronal cells, collectively termed the 'neuroglia' undertake distinct and critical functions in 
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such as immune surveillance, blood-brain barrier maintenance, genesis of myelin (the insulating 
sheath around neurons) and regulation of electrochemical signalling [21-23]. Neuroglial subclasses 
consist of the oligodendrocytes [that co-exist with their parent population- the oligodendrocyte 
precursor cells (OPCs)], microglia, and astrocytes. These subclasses have unique structural, 
functional and molecular properties and can therefore be predicted to show important differences in 
their uptake and handling of synthetic materials. Indeed, our recent studies point to significant inter-
cellular differences in toxicity and transfection levels between neuroglia, the reasons for which are 
unknown [12,14,24]. The neurogliaform an extensive cellular network and outnumber neurons by a 
factor of approximately ten. Consequently, understanding particle handling by this major class of 
cells, is a critical component in understanding interactions between synthetic biomaterials and the 
CNS as a whole.  
 
A small number of studies have reported MP uptake by neuroglial cells [25,26] but no study to date 
has systematically compared particle uptake and handling by individual neuroglial subclasses. Here, 
we have assessed the uptake and intracellular processing of a single type of MP (of specific size and 
formulation) by oligodendrocyte lineage cells ie. oligodendrocytes and OPCs derived from primary 
cell cultures. These findings were collated with data from our previous studies in astrocytes [27] 
and microglia [24] (also derived from primary cultures) to provide, for the first time, comparative 
data on the uptake characteristics and particle handling by these major subclasses of CNS cells.  
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Materials and Methods 
Reagents and equipment: Tissue culture-grade plastics, media, and media supplements were from 
Fisher Scientific (Loughborough, UK) and Sigma-Aldrich (Poole, UK). Recombinant human plate- 
let-derived growth factor (PDGF-AA) and basic fibroblast growth factor (FGF2) were from 
Peprotech (London, UK). Monoclonal rat anti-MBP was from Serotech (Kidlington, UK), 
monoclonal mouse anti-A2B5 was from Sigma-Aldrich (Poole, UK), and secondary antibodies 
(FITC-conjugated) were from Jackson ImmunoResearch Laboratories Inc. (West Grove, PA, USA). 
Mounting medium with DAPI (4’,6-diamidino-2-phenylindole) was from Vector Laboratories 
(Peterborough, UK). Paramagnetic, carboxyl-modified SpheroTM Nile Red fluorescent MPs 
(diameter 0.20 – 0.39 µm, iron content 15 – 20% w/v) were obtained from Spherotech Inc. (Lake 
Forest, Illinois, USA). We have observed that their fluorophore does not leach, and their emission 
spectra remain stable following long periods of storage, making these an optimal choice for this 
study.  
 
Particle characterization: FTIR spectroscopic analysis was carried out using a Perkin Elmer 
Spectrum 100 spectrometer fitted with an ATR (attenuated total reflection) sampling unit. For the 
sample measurement, 32 scans in the region from 650 to 4000 cm-1 were accumulated with a 
resolution of 4 cm-1. Powder XRD analysis on the iron oxide component of the particles was carried 
out using a Bruker D8 Advance diffractometer with Cu Kα1 radiation (λ = 1.542 Å). The diffract 
pattern was collected from 2θ = 5° to 80°, at a step size of 0.009° and a step time of 120 s. The 
particle size of iron oxide was estimated using Scherrer analysis on the most intense peak (311).  
 
OPC and oligodendrocyte cultures for uptake experiments: The care and use of animals was in 
accordance with the Animals (Scientific Procedures) Act of 1986 (United Kingdom) with approval 
by the local ethics committee. Primary mixed neuroglial cultures were prepared from cerebral 
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cortices of Sprague-Dawley rats at postnatal day 1-3, based on an established protocol [28]. 
Cultures were maintained in D10 medium (DMEM supplemented with 10% fetal bovine serum, 2 
mM glutaMAX-I, 1 mM sodium pyruvate, 50 U mL-1 penicillin, and 50 µg mL-1 streptomycin) at 
37°C in 5% CO2/95% humidified air for 8-10 days, then shaken for 2 h on a rotary shaker at 200 
rpm. This medium, containing largely microglia was discarded, fresh D10 medium added, and 
flasks shaken overnight at 200 rpm. This medium, containing largely OPCs, was transferred to non-
tissue-culture grade petri dishes, to which microglia, but not OPCs readily attach, reducing 
microglial contamination. After 30 min, unattached cells were resuspended in either OPC 
maintenance medium (OPC-MM: DMEM supplemented with 2 mM glutaMAX-I, 1 mM sodium 
pyruvate, 10 nM biotin, 10 nM hydrocortisone, 30 nM sodium selenite, 50 µg mL-1 transferrin, 5 µg 
mL-1 insulin, 0.1% bovine serum albumin, 50 U mL-1 penicillin, 50 µg mL-1 streptomycin, 10 ng 
mL-1 PDGF-AA, and 10 ng mL-1 FGF2) for OPC cultures, or in Sato medium (DMEM 
supplemented with 2 mM glutaMAX-I, 1 mM sodium pyruvate, 1X N2 supplement, 30 nM 
thyroxine, 30 nM triiodothyronine, 50 U mL-1 penicillin, and 50 µg mL-1 streptomycin) to generate 
oligodendrocyte cultures. Cells were plated onto PDL-coated glass coverslips in 24-well plates (0.3 
mL/well, at 3 x 104 cells/cm2). OPC cultures were maintained for 24 h before incubation with MPs, 
to allow cell adherence and re-growth of processes. Oligodendrocyte cultures were maintained for 7 
days (50% medium changes every 2-3 days) to allow cell differentiation, before incubation with 
MPs. Cells were then incubated with 2-50 µg mL-1 MPs for 1 – 24 h. For long-term studies, OPCs 
were pulse-labeled with MPs for 24 h, then switched to Sato medium and maintained for 1 month. 
Control cultures were treated with equal volumes of fresh medium, without MPs. Samples were 
washed with PBS, then fixed and either immunostained, or processed for Perl's Prussian blue 
histochemical staining. 
 
Methodological considerations - extracellular particle adherence: OPC and oligodendrocyte 
cultures are not as strongly adherent to PDL-coated coverslips as microglial and astrocyte cultures. 
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This presented a methodological problem for particle uptake experiments with regard to the 
removal of extracellular particles when terminating incubations. In previous work, extensive 
washing with PBS was necessary to reduce non-specific binding of MPs to minimal levels, and this 
was well tolerated by microglial and astrocyte cultures, resulting in minimal cell detachment. In the 
present study a similar washing protocol resulted in the loss of many OPCs and oligodendrocytes, 
even without the prior addition of MPs. To minimize the loss of cells, several washes were 
performed by gently applying PBS to the walls of culture wells. 
 
Toxicity assessment: Initial experiments used a 3-[4,5-dimethylthiazol-2-yl]-2, 5-
diphenyltetrazolium bromide (MTS) assay to assess MP toxicity in OPCs and oligodendrocytes, as 
described earlier, for comparison with astrocyte and microglia data [24,27]. However, in our hands, 
typically low levels of MTS reduction to formazan were consistently found in both control and MP-
treated cultures, which was not deemed sufficiently sensitive to accurately assess toxicity. 
Therefore, epifluorescence microscopy was used to count the pyknotic and total (healthy plus 
pyknotic) nuclei per microscopic field, as measures of MP-related toxicity. A minimum of five 
fields were counted for every condition. 
 
Immunocytochemistry: Washed cells were fixed with 4% paraformaldehyde [PFA; room 
temperature (RT); 25 min] then washed again. For staining, cells were incubated with blocking 
solution (5% serum in PBS, with 0.3% Triton X-100 for MBP; RT; 30 min), then with primary 
antibody in blocking solution (A2B5 1:200; MBP 1:200; 4°C; overnight). A2B5 and MBP are 
widely-used markers of the oligodendroglial lineage: the A2B5 antibody recognizes cell surface 
ganglioside epitopes; MBP is one of the major protein constituents of myelin, and is used to label 
late-stage oligodendrocytes. Cells were then washed with PBS, incubated with blocking solution 
(RT; 30 min), and incubated with the appropriate FITC-conjugated secondary antibody in blocking 
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solution (1:200; RT; 2 h). Finally, coverslips were washed with PBS and mounted with the nuclear 
stain DAPI.  
 
Fluorescence microscopy & image analysis: Samples were imaged using fixed exposure settings on 
an Axio Scope A1 fluorescence microscope (Carl Zeiss MicroImaging GmbH, Goettingen, 
Germany), and the images merged using Adobe Photoshop CS3 (version 10.0.1). The purity of each 
culture was determined by scoring at least 100 DAPI-stained nuclei for coincidence with A2B5 or 
MBP staining. Z-stack fluorescence images of samples were created using fixed exposure settings 
on a Nikon Eclipse 80i microscope fitted with a CA742-95 camera (Hamamatsu Photonics, 
Hamamatsu, Japan), with manual focus stepping at 0.5 or 1.0 µm, and the image manipulations 
performed using Nikon NIS Elements (version 3.00). The proportion of A2B5+ OPCs or MBP+ 
oligodendrocytes with coincident Nile Red fluorescence was assessed (minimum 100 DAPI-stained 
nuclei for each concentration and timepoint), with the proportion of MP-labeled cells exhibiting any 
perinuclear MPs also being recorded. Some samples were also imaged using a BioRad MRC1024 
confocal laser scanning microscope. 
 
Semi-quantitative assessment of MP uptake: It was deemed unsuitable to assess levels of uptake by 
means of a fluorescence plate reader, or in terms of incorporated iron per cell, as these techniques 
quantify the total fluorescence or iron present in a culture, and therefore assume an even distribution 
between cells. Such techniques would not enable the determination of uptake heterogeneity within 
the cell population, as observed in our cultures. A flow cytometry approach was also considered and 
rejected, as it is likely that extracellular MPs adherent to the plasma membrane would lead to a 
number of ‘false positives'. Microscopic cell counting analysis was therefore considered the most 
appropriate method to assess whether MPs were intracellular, or merely extracellularly attached to 
plasma membrane. To ensure that cellular uptake was judged correctly, z-stack analyses were 
performed for both OPC and oligodendrocyte cultures to confirm that MPs were intracellular, rather 
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than adherent to the plasma membrane (minimum of 100 cells for all concentrations and 
timepoints). Oligodendrocyte cultures were particularly problematic, as MPs were often observed 
amongst their extensive, lipid-rich processes however, from the z-stack analyses it was apparent 
that MPs were external to the oligodendrocyte processes. Therefore, for these analyses, only MPs 
that were clearly within the oligodendrocyte soma, the main cell body, were considered to be 
intracellular, and all other particles were deemed to be extracellular. The level of MP uptake in 
individual cells was assessed in a semi-quantitative manner by comparison with the average cross-
sectional area of an OPC/oligodendrocyte nucleus, and scored as either ‘low’ (<10% of the area of 
an average nucleus), ‘medium’ (10 – 50%), or ‘high’ (>50%). We consider that such detailed 
microscopic assessment of MP uptake more accurately reflects the heterogeneity that is typically 
found in primary cell cultures. 
 
Perls’ Prussian blue staining: Washed samples were fixed with 4% PFA (RT; 25 min), then 
washed again. Samples were incubated with 2% potassium ferricyanide in 2% HCl for 30 min, then 
washed three times with distilled water and mounted without DAPI. Images were then taken using 
light microscopy, to visualize intracellular iron, and fluorescence microscopy, to visualize Nile Red 
particle fluorescence. Images were merged to assess colocalization of iron deposits with 
fluorescence. 
 
Scanning electron microscopy: MPs in OPC-MM were air-dried onto aluminium stubs and 
visualized uncoated using a high resolution field emission SEM (Hitachi S4500) operated at an 
accelerating voltage of 5 kV. 
 
Transmission electron microscopy: Microglial, astrocyte and OPC cultures were established on 
PDL- or polyornithine-coated aclar sheet (microglial [24] and astrocyte [27] cultures were prepared 
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as described previously), cut to fit a 24-well plate (0.3 mL/well, at 6 x 104 cells/cm2), then 
incubated with 20 µg mL-1 MPs for 4 or 24 h. Samples were fixed with 2.5% glutaraldehyde [in 
sodium cacodylate buffer (SCB); RT; 2 h], then washed with SCB. Samples were postfixed with 
1% osmium tetroxide in SCB for 1 h, washed with SCB, dehydrated in a graded series of ethanol, 
then infiltrated with Spurr resin, before polymerization at 60°C for 16 h. To obtain sections, the 
block was trimmed to expose the aclar sheet which was peeled off, leaving the cells in the resin. 
Ultrathin sections were then cut parallel to the original plane of the sheet on a Reichert Ultracut E 
ultramicrotome, mounted on 200 mesh thin bar copper grids, and stained with 2% uranyl acetate in 
70% ethanol (RT; 20 min) and 2% Reynolds lead citrate (RT; <5 min). A minimum of three 
sections were examined for each cell type using a JEOL 100-CX transmission electron microscope 
operated at 100 kV. Images were acquired using a SIS systems Megaview III digital camera 
(Olympus). 
 
Statistical analysis: Data were analyzed using GraphPad Prism statistical analysis software. Data 
are expressed as mean ± SEM. The number of experiments (n) refers to the number of mixed glial 
cultures from which OPC or oligodendrocyte cultures were derived, with each primary culture 
being established from a different rat litter. Data were analyzed by two-way analysis of variance 
(ANOVA), with Bonferroni’s multiple comparison post-tests for post hoc analysis. 
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Results 
Characterization of MPs 
The MPs used here have a multilayered design (Figure 1a), comprising a polystyrene core (stained 
with the fluorophore nile red), coated with a polystyrene/iron oxide composite layer; we have found 
that these are stable in physiological media and consistently perform robustly under our 
experimental conditions, justifying their use in this study. These 'test' MPs are relatively large (200 
– 390 nm diameter; mean = 360 nm); we have previously justified the use of particles of this 
diameter for in vivo biological applications [24]. Indeed, particles of up to 1 µm diameter have been 
used to image cells transplanted into the CNS without demonstrable effects on even complex 
biological functions such as myelination [29] and other particles, including functionalized 
transfection grade ones are of comparable diameter [29–32].  
 
Batch-to-batch variability can occur during MP synthesis, and particle size is an important factor in 
cellular uptake and processing [19]. Therefore, MPs were analyzed by scanning electron 
microscopy (SEM) for size and shape assessments; our data were consistent with our previous 
findings, showing that the particles used here were regular in shape, and within the size range 
reported by the manufacturer (Figure 1b). Perls’ Prussian blue staining of cells which had been 
pulse-labeled with these MPs for 24 h revealed the presence of iron coincident with Nile Red 
fluorescence at 24 h (Figures 1c & d), and at 30 days post-treatment (data not shown). This 
demonstrates the reliability of fluorescence as an indicator of MP presence, and suggests the 
stability of MPs in the culture media and the cells. No blue staining was observed after Perls’ 
staining of control cultures. The zeta potential of the particles was measured as -23.02 mV with ca. 
1.63 × 106 carboxyl groups per particle (data provided by supplier, Spherofluor Inc.). The FTIR 
spectrum of these Spherotech particles was dominated by the polystyrene component (Figure 1 e) 
with a small number of caroboxylic groups, shown as νC=O (C=O stretching) at 1707 cm-1. The 
powder XRD pattern (Figure 1f) revealed that the iron oxide crystallites in the particles are of an 
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inverse spinel structure, eg. Fe3O4 (magnetite) or gamma-Fe2O3 (maghemite). However, due to the 
small crystal size or low crystallinity of the iron oxide, the diffraction peaks are broad and of low 
intensity. This is also partly due to the predominant amount of polystyrene (ca. 80%) present in the 
particles. The average crystal size was also estimated to be around 18.5 nm in diameter using 
Scherrer analysis on the diffraction peak (311).   
 
OPC Culture Characteristics 
Phase contrast microscopy of untreated and MP-treated cultures revealed phase-bright cells with 
bipolar morphologies characteristic of OPCs (Figure 2a). High purity OPC cultures were routinely 
derived, as assessed by immunostaining for the OPC marker A2B5 (95.4 ± 0.9%; n = 4), and DAPI-
staining showed typical round or oval nuclei (Figure 2a, inset). 
 
Concentration- and Time-Dependence of MP Uptake and Perinuclear Localization in OPCs 
Fluorescence microscopy, including z-stack and confocal analyses, confirmed the intracellular MPs 
in OPCs (Figure 2b; confocal data not shown) with particles typically observed in small clusters. 
MP uptake was time- and concentration-dependent, with the highest dose and longest exposure 
tested resulting in labeling of ca. 60% of A2B5+ cells (Figure 2c). Concentrations of 20 and 50 µg 
mL-1 labeled a significantly greater percentage of cells than 2 µg mL-1, at all timepoints. The extent 
of MP-uptake by individual cells was heterogenous, therefore a semi-quantitative approach was 
employed to classify categories of uptake as described previously [24,27]. Under all conditions, the 
majority of MP-labeled OPCs exhibited a ‘low’ level of particle accumulation. At 4 and 24 h, a 
small percentage of MP-labeled cells exhibited ‘medium’ levels of uptake at all concentrations with 
‘high’ levels of uptake rarely observed (Table 1). The percentage of labeled OPCs with MPs in a 
perinuclear localization was time- and concentration-dependent (Figure 2d). Intranuclear particles 
were not observed using confocal or z-stack analyses. 
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Oligodendrocyte Culture Characteristics 
Oligodendrocytes were derived from high purity parent OPC cultures, with 70.3 ± 1.3% of cells 
staining positive for the late-stage oligodendrocyte marker myelin basic protein (MBP; Figure 3a). 
All stages of the oligodendroglial lineage are typically present in such cultures, and our own 
analyses show that a further ~25% stain for earlier markers such as NG2 and O4, with the 
remainder (<5%) being microglial contamination (data not shown) [33]. Cells were phase-bright, 
with multipolar morphologies, including the complex highly-branched, membrane elaborating 
morphologies typical of mature oligodendrocytes. 
 
Concentration- and Time-Dependence of MP Uptake and Perinuclear Localization in 
Oligodendrocytes 
Z-stack and confocal fluorescence analyses, confirmed intracellular MPs in oligodendrocytes, 
including perinuclear accumulations (Figure 3b; confocal data not shown). The percentage of 
labeled oligodendrocytes was time- and concentration-dependent, with the greatest dose and 
exposure tested resulting in MP-labeling of ca. 45% of MBP+ cells (Figure 3c). MP concentrations 
of 20 and 50 µg mL-1 labeled a significantly greater percentage of MBP+ cells than 2 µg mL-1, at all 
timepoints. Heterogeneity in uptake was apparent and this was assessed semi-quantitatively using 
the same criteria used for scoring OPCs (Table 2). Under all conditions, the majority of MP-labeled 
cells exhibited a ‘low’ level of particle accumulation. At 4 and 24 h, oligodendrocytes with 
‘medium’ levels of MP accumulation were observed with ‘high’ levels of accumulation rarely 
observed (at the greatest MP concentration and incubation time) (Table 2). By 24 h, cultures 
exposed to 2 and 5 µg mL-1 MPs exhibited a time-dependent increase in the percentage of MP-
labeled MBP+ oligodendrocytes with perinuclear particles (Figure 3d). 
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Comparison of MP Uptake in OPCs and Oligodendrocytes 
When data for OPCs and oligodendrocytes were compared, the proportions of labeled cells were 
similar at 1 h post-MP addition (Figures 2c & 3c). At subsequent time points, a greater percentage 
of OPCs than oligodendrocytes were MP-labeled with the exception of the 24 h incubation with 20 
µg mL-1 MP (Tables 1 and 2). With respect to cells scored as having ‘low’ levels of uptake, the 
accumulations of MPs present within OPCs were typically larger than those within 
oligodendrocytes (compare Figures 2b and 3b, which show typical levels of MP accumulation). 
Further, cells at more advanced stages of oligodendrocyte differentiation (judged by 
number/complexity of processes), contained smaller particle accumulations than cells with 
relatively immature and less branching morphologies (data not shown). This suggests an inverse 
relationship between cellular maturity and capacity for MP uptake. For both cell types, the 
percentage of cells with ‘medium-high’ levels of MP uptake was time- (p<0.001; two-way 
ANOVA; n = 4) and concentration-dependent (p<0.001; two-way ANOVA; n = 4), suggesting that 
the uptake mechanism is non-saturable in the time-frame examined.  
 
Assessment of MP toxicity in OPCs and oligodendrocytes  
No significant effects of MPs were observed in OPC or oligodendrocyte cultures with respect to (a) 
cell adherence, judged by number of DAPI-labeled nuclei (either healthy or pyknotic) per 
microscopic field (Figures 4a & b), and (b) cell death, judged by the percentage of nuclei 
exhibiting pyknotic features (ie. shrunken or fragmenting morphologies; Figures 4c & d). OPC and 
oligodendrocyte cultures appeared morphologically similar to controls at 24 h, and this was also 
true for oligodendrocytes at one month post- pulse labeling with MPs (data not shown). No effects 
of MPs were noted on the time taken to reach confluence or extent of membrane elaboration in OPC 
or oligodendrocyte cultures. 
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Intercellular differences in extent of MP uptake 
Data from OPCs and oligodendrocytes were combined with data obtained from rat astrocytes [27] 
and microglia [24] using identical particle concentrations and timings of exposure. From these 
analyses, there are clear differences between individual neuroglial classes in the rate and extent of 
MP accumulation, with the relationship with respect of these parameters being: microglia > 
astrocytes > OPCs > oligodendrocytes (Figures 5a-d). Comparing the extent of MP-uptake at 4 h 
highlights the rapid labeling of >90% of microglia, even with ‘low’ MP concentrations, compared 
to the gradual time- and concentration-dependent uptake observed in the other cell types (Figure 
5e). Intercellular differences in perinuclear particle localization were also apparent, with microglia 
showing the most rapid and extensive accumulation (Figure 5f).  
 
Intercellular differences in MP processing in cells 
Transmission electron microscopy (TEM) analyses were used to study the intracellular disposition 
of MPs. This is a time consuming and technically demanding method compared with other 
histological approaches, but we consider that this is the most robust ultrastructural approach to 
obtain morphological data on modes of particle uptake, evidence of vacuolar internalization, 
perinuclear trafficking, and lysosomal degradation/end products of MP breakdown, with high 
resolution. Electron dense MPs were easily detected in within cells. Astrocytes and OPCs contained 
morphologically intact MPs, generally observed to be free in the cytosol, including the perinuclear 
accumulations (Figures 6a & b) [27]. MP clusters were strikingly smaller in OPCs compared with 
astrocytes, supporting our observations using fluorescence microscopy (Figures 6a & b). By 
contrast, microglia revealed extensive MP accumulations seen associated with multilamellar bodies, 
likely to be lysosomes (Figure 6c). In contrast to astrocytes and OPCs, MPs appeared to be 
undergoing extensive degradation in microglia (Figure 6c, inset). Following 24 h MP exposure 
toxicity was not observed in OPCs, oligodendrocytes, or astrocytes [27], but was marked in 
microglial cultures [24] (Figure 6d).  
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Discussion 
To the best of our knowledge, this is the first investigation into inter-cellular differences in MP 
uptake and handling by the major neuroglial subtypes. Our data reveal that these subpopulations 
exhibit key differences in the uptake and intracellular processing of MPs. We consider that such 
variations could have important implications for the biological utility of MP platforms for neural 
tissue engineering applications. As such, we consider that the findings have broader implications for 
the design and development of novel neurocompatible materials for regenerative medicine, and 
associated protocols for their use. 
 
Most work to date evaluating cellular MP uptake and handling has utilized cell lines [34-38]. This 
has yielded valuable data but warnings about cell line identity have been made since the 1950s, with 
many instances of published work carried out in misidentified cell lines [39-41]. Cell lines possess 
an altered physiology compared with the corresponding primary cells and behave in a relatively 
homogenous clonal manner. Consequently, their properties may not represent biological variations 
that exist in vivo that reflect cell proliferation, differentiation and varying states of biological 
activation (particularly relevant in neurological injury), all of which will influence the outcomes of 
MP use. Cell lines also show relatively high survival/proliferation rates and resistance to adverse 
stimuli such as cell death signals; continuous passage of cells without robust quality control also 
risks chronic contamination by mycoplasma - such ‘cryptic’ contamination can alter cell structure, 
metabolism and growth, all of which can impact the interpretation of data [42]. These 
considerations, combined with the risk of cellular aneuploidy, can make cell lines a relatively poor 
model for toxicity testing [42,43]. This is an issue of high relevance to nanotechnology, where the 
neurotoxicity of nano- and micro- sized particles is currently an issue of major public and scientific 
concern. As such, we contend that cells derived from primary cultures, as used here, are of higher 
biological relevance than cell lines, particularly when developing protocols for translational 
applications.   
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MP uptake is dependent on endocytosis (macropinocytosis, clathrin-, and caveolin-mediated 
uptake) in mammalian cells [2,19,44] but little data exists on MP uptake mechanisms in primary 
neuroglia. The cells studied here display a range of endocytotic mechanisms overall, and 
differences in MP accumulation likely relate to variations in basal levels of endocytosis. We can 
predict that the specific endocytotic pathways utilized by each cell type, and their levels of activity, 
closely correlate with the functional role for each cell type. For example, microglia are phagocytic 
cells and continuously survey their microenvironment using highly motile processes, removing 
debris and foreign materials; they utilize all endocytotic mechanisms, including receptor-mediated 
endocytosis, macropinocytosis and phagocytosis [24,45] The astrocytes, in turn, have a major role 
in uptake of extracellular biomolecules, and possess well-developed endocytotic machinery; we 
recently showed that astrocytes take up the MPs studied here, by macropinocytosis and coated pit 
mechanisms [27]. In line with their broad regulatory and defence roles, microglia and astrocytes 
showed extensive and rapid particle uptake. By contrast, cells of the oligodendrocyte lineage have 
specialist roles in generating oligodendrocytes and the myelin sheath [23]. As such, we can predict 
that endocytotic cycling in these cells is lower, an expectation strikingly reflected in the finding that 
percentages of labeled oligodendroglial cells are about half that observed in astrocytes and 
microglia, along with substantially lower levels of MP accumulation. We are not aware of studies 
quantifying endocytotic mechanisms across neuroglial cells, and such a comparison will be a pre-
requisite to providing formal proof of this idea.   
 
A further factor influencing uptake could be the relative extent of cell membrane available to 
undertake endocytosis. Astrocytes display characteristically flattened morphologies and large 
amounts of membrane. By contrast, OPCs and oligodendrocytes have small oval or round cell 
bodies, and, as far as we are aware, their processes are not involved in particle uptake - observations 
supported by our histological analyses. Differences in cell surface area may account for the 
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differences in particle uptake, and it is not clear whether using particles of altered dimensions may 
result in greater MP accumulation [19,46]. Also, in line with their phagocytic role, microglia cells 
appear to inactivate particles by sequestration within vesicles and active lysosomal degradation. 
Extensive particle accumulation in conjunction with iron toxicity post-degradation is the likely 
pathological correlate of MP toxicity in these cells [47]. By contrast, in the other cell types, 
particles appeared to be relatively stable morphologically with negligible associated toxicity.  
 
We consider that the overall profiles of MP uptake and handling exhibited by neuroglia, as reported 
here, have broader predictive value with biological implications regarding MP use in neural tissue 
engineering (see Figure 7 for a schematic overview). First, if using MPs for cell labeling and 
imaging of neural transplant populations, then protocols will need to be individually tailored by cell 
type, with OPCs requiring higher particle concentrations and incubation times, to achieve high 
efficiency labeling. A previous study in an OPC cell line suggests that sub-10 nm magnetic 
nanoparticles show extensive accumulation in these cells [9] indicating that MP physicochemical 
properties (such as size, shape, coating, geometry and charge) can be tailored to achieve optimal 
labeling [8].  
 
Second, while MPs are effective transfection agents, the specific mode of intracellular trafficking of 
particles will exert an important influence on transfection levels achieved. Efficient perinuclear 
accumulation of MPs (a pre-requisite for DNA delivery [48]) in microglia, suggests that MPs could 
act as effective transfection agents in these cells, but we recently reported that microglial 
transfection was rarely achieved using transfection grade MPs [24]; particle sequestration and 
breakdown provides a reasonable explanation for our observations and indeed, there are few reports 
of non-viral, plasmid based transfection of microglia. Microglial transfection is a desirable goal, 
allowing immunomodulation in neurological injury, but our results indicate that there are significant 
'intracellular barriers' to MP-mediated transfection in microglia that will need to be overcome, using 
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strategies such as MP targeting to particular intracellular compartments to evade degradation 
mechanisms. By contrast, the relative stability and non-sequestration of MPs in astrocytes and 
OPCs, is in line with our findings that both cell types can be transfected (with the same transfection 
grade MPs tested in microglia), albeit with major differences in maximal transfection levels (ca. 
55% for astrocytes versus ca. 23% for OPCs) achieved [12,14]. This trend correlates with the 
relative extent of basal MP uptake in astrocytes versus OPCs. There is a sharp drop in MP mediated 
transfection of oligodendrocytes (up to 4%; unpublished observations) despite perinuclear MP 
accumulation. This could be related to lower particle uptake but successful transfection may also 
depend on other factors. For example, nuclear breakdown during mitosis may facilitate entry of 
nucleic acids, so proliferative populations such as astrocytes/OPCs may be relatively amenable to 
MP-mediated transfection compared to non-dividing cells such as oligodendrocytes [17].  
 
Third, robust microglial uptake of MPs is beneficial for imaging sites of CNS injury/disease [49]. 
However, rapid and extensive particle uptake by endogenous microglia may limit particle uptake by 
other cell types where mixed cell populations of neural cells exist, for example, neurological injury 
sites [24]. Such considerations suggest that microglial MP uptake is a significant ‘extracellular 
barrier' when considering applications such as direct MP mediated drug/gene delivery to the CNS, 
that may potentially require strategies such as immunosuppression, cell targeting approaches or 
variations in particle physiochemical properties, to reduce microglial uptake. Further, MP related 
toxicity in microglia could become a cause of secondary CNS pathology, therefore particle doses 
and formulations must be selected with caution. 
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Conclusions 
CNS neuroglial subclasses show considerable variability in MP uptake and intracellular handling. 
Such variations are likely related to differences in (a) their functional roles; (b) basal endocytotic 
activity; and (c) extent of membrane elaboration. We predict that the differences have implications 
for the use of the MP platform in neural tissue engineering and translational applications such as 
imaging, cell labeling and gene/drug delivery. It is therefore essential for future work to take 
account of the complexity of neuroglial responses to synthetic materials, in order to optimize and 
refine the use of MPs for neural regenerative applications. Such work will need to be informed by a 
detailed understanding of the relationship between the physicochemical properties of MPs and 
neuroglial uptake, processing and toxicity - parameters that are poorly documented at present.  
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Future Perspective 
 There is a critical knowledge gap in nanotechnology and neurotoxicology, regarding the influence 
of the chemistry of materials platforms on the biology of CNS cells [50]. Such information is vital 
to robustly evaluate the utility of novel materials for the development and optimization of new 
therapeutics. Further studies will need to characterize neuroglial cell interactions with MPs of a 
range of physicochemical properties to identify those with optimal features for specific biomedical 
applications. For each cell type, such investigations should include ultrastructural analyses of 
particle fate; endocytotic blocker studies to establish specific uptake mechanisms; microarray 
analyses for detailed toxicity analysis; evaluation of vesicular trafficking of MPs, to develop 
particles with the potential for endosomal escape or to suggest the specific endocytotic mechanisms 
to which MPs should be preferentially targeted. 
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Summary points 
 Non-neuronal cells of the CNS, termed the neuroglia, derived from primary cultures, show 
significant differences in MP uptake. 
 Microglia show the most rapid and extensive MP uptake followed by astrocytes; 
oligodendrocyte precursor cells and oligodendrocytes show comparatively less uptake.  
 MPs undergo extensive degradation in microglia whereas particles appear relatively intact in 
the other cell types. Significant microglial toxicity was observed at concentrations that were 
non-toxic in the other cell types. 
 The differences in the extent of MP uptake and processing in the neuroglia could have 
significant implications for MP use in neural tissue engineering applications. 
 Rapid uptake and degradation of MPs in microglia could represent a significant 
'extracellular barrier' for direct MP use (in gene/drug delivery) in the CNS. Such degradation 
is also a major 'intracellular barrier' in applications such as transfection. 
 MP stability in astrocytes and oligodendroglial cells indicates that MPs are compatible with 
these cells, but the relative levels of cellular uptake will determine the efficacy of MP use. 
 Utilising cells derived from primary cultures, as in the current study, offers several 
advantages over cell lines that are widely employed in bio-nanotechnology research.  
 Future studies will need to characterize relationships between MP physicochemical 
properties and cellular uptake, processing and toxicity in CNS cells, to identify optimal 
neurocompatible materials. 
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